Abaxis (ABAX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq touch new peaks as Treasury yields cool, oil slips
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Nasdaq notches record high close as investors focus on earnings
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend
October 24, 2017 4:01 PM EDTUNION CITY, Calif., Oct. 24, 2017 /PRNewswire/ -- Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the second fiscal quarter ended September 30, 2017.
Second quarter results include:
Revenues of $58.9 million, up 1% over last year's comparable quarter. Veterinary market revenues of $48.5 million, up 1% over last year's comparable quarter. International revenues of $11.9 million, up 3% over last year's comparable quarter. Revenues from sales of consumables, which include reagent discs, hematology... More


